Barrington Research Reiterates Outperform Rating for DENTSPLY SIRONA (NASDAQ:XRAY)

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report)'s stock had its "outperform" rating reissued by equities researchers at Barrington Research in a report released on Tuesday,Benzinga reports. They presently have a $21.00 price target on the medical instruments supplier's stock. Barrington Research's price target suggests a potential upside of 27.58% from the company's previous close.

A number of other brokerages also recently issued reports on XRAY. Piper Sandler dropped their price target on DENTSPLY SIRONA from $20.00 to $16.00 and set a "neutral" rating for the company in a research report on Wednesday, April 30th. Wall Street Zen raised shares of DENTSPLY SIRONA from a "hold" rating to a "buy" rating in a report on Sunday, July 13th. Morgan Stanley downgraded shares of DENTSPLY SIRONA from an "overweight" rating to an "equal weight" rating and set a $14.00 price objective for the company. in a report on Tuesday, April 15th. Needham & Company LLC restated a "hold" rating on shares of DENTSPLY SIRONA in a research report on Monday. Finally, UBS Group cut their price objective on DENTSPLY SIRONA from $27.00 to $25.00 and set a "buy" rating for the company in a report on Friday, May 9th. Ten analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $19.60.

DENTSPLY SIRONA Stock Performance

NASDAQ XRAY traded down $0.39 during trading on Tuesday, hitting $16.46. 2,077,441 shares of the company's stock traded hands, compared to its average volume of 2,528,443. The stock has a market capitalization of $3.28 billion, a price-to-earnings ratio of -3.63, a PEG ratio of 1.20 and a beta of 0.94. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.76 and a current ratio of 1.10. The business has a 50 day moving average of $16.05 and a 200-day moving average of $16.24. DENTSPLY SIRONA has a 12-month low of $12.16 and a 12-month high of $27.95.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last posted its earnings results on Thursday, May 8th. The medical instruments supplier reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.14. DENTSPLY SIRONA had a positive return on equity of 14.31% and a negative net margin of 24.42%. The firm had revenue of $879.00 million for the quarter, compared to the consensus estimate of $854.75 million. During the same quarter in the prior year, the business posted $0.42 earnings per share. The business's quarterly revenue was down 7.8% on a year-over-year basis. As a group, equities research analysts anticipate that DENTSPLY SIRONA will post 1.84 earnings per share for the current fiscal year.

Institutional Investors Weigh In On DENTSPLY SIRONA

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC lifted its stake in DENTSPLY SIRONA by 119.4% in the first quarter. AQR Capital Management LLC now owns 6,346,685 shares of the medical instruments supplier's stock valued at $93,423,000 after buying an additional 3,453,662 shares during the last quarter. Nuance Investments LLC boosted its holdings in shares of DENTSPLY SIRONA by 25.0% in the fourth quarter. Nuance Investments LLC now owns 13,545,981 shares of the medical instruments supplier's stock worth $257,103,000 after buying an additional 2,708,097 shares during the period. Norges Bank purchased a new position in DENTSPLY SIRONA during the fourth quarter valued at approximately $45,730,000. Goldman Sachs Group Inc. lifted its holdings in shares of DENTSPLY SIRONA by 827.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier's stock valued at $36,378,000 after buying an additional 2,172,343 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of DENTSPLY SIRONA by 18.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 12,549,242 shares of the medical instruments supplier's stock valued at $238,186,000 after acquiring an additional 1,975,404 shares during the last quarter. Hedge funds and other institutional investors own 95.70% of the company's stock.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.